The Monitoring System for Adverse Events Following Immunization became fully operational
in late 1978 in all 50 States, New York City and Washington, DC This system compiles …

Background Pertussis vaccination during pregnancy can prevent 91% of infant infections. In
2015, antenatal pertussis vaccination programs were introduced across Australia. Methods …

Adult pertussis vaccination is increasingly recommended to control pertussis in the
community. However, there is little data on the duration and kinetics of immunity to pertussis …

Extensive limb swelling (ESL) after a booster dose of acellular pertussis (aP) containing
vaccine can cause concern and has the potential to be confused with cellulitis. In the United …

Abstract▲ Boostrix® US formulation (hereafter referred to as Tdap) is a formulation of
reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed onto …

Aim: To observe reactogenicity of a three-component acellular pertussis (aP) vaccine
simultaneously given with dT-IPV vaccine at the age of 4 years. Results: Of 813 subjects …

Extensive local reactions have been reported after booster doses of diphtheria and tetanus
toxoid and acellular pertussis vaccine, but few data are available on revaccination after …

Background: The rising incidence of pertussis amongst adults and adolescents in
industrialised countries could be reduced by replacing tetanus and diphtheria (Td) boosters …

Introduction Two types of vaccines are currently licensed for use against pertussis: whole-
cell (wP) and acellular pertussis (aP). There is evidence that wP confers more durable …

Minor adverse events were evaluated in a comparative efficacy trial in Germany in infants
who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine …